7 studies found for:    SB-728-T
Show Display Options
Rank Status Study
1 Active, not recruiting Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
Condition: HIV
Intervention: Genetic: SB-728-T
2 Completed Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
Conditions: HIV;   HIV Infection
Intervention: Biological: SB-728-T
3 Active, not recruiting Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Conditions: HIV Infection;   HIV Infections
Intervention: Genetic: SB-728-T
4 Recruiting Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Genetic: SB-728mR-T;   Drug: Cyclophosphamide
5 Completed Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV
Conditions: HIV;   HIV Infections
Interventions: Biological: ZFN modified T cells;   Other: Structured Treatment Interruption
6 Recruiting Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
7 Recruiting Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Condition: Prevention & Control
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole

Indicates status has not been verified in more than two years